<DOC>
	<DOC>NCT00188604</DOC>
	<brief_summary>The primary objective of this study to assess the effectiveness of selenium compared to placebo in reducing the lymphedema in-patients with breast cancer. Secondary objectives are to assess the impact of selenium on patient's quality of life and to assess the incidence of adverse effects of selenium therapy.</brief_summary>
	<brief_title>The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<mesh_term>Selenious Acid</mesh_term>
	<mesh_term>Sodium Selenite</mesh_term>
	<criteria>patients with clinically documented lymphedema of upper limb secondary to breast cancer management (surgery axillary nodal dissection, and radiotherapy) patients who have had other modalities of management can be included, e.g. physical therapy, pharmacological therapy ECOG performance 02 informed consent active cellulitis/skin infection of the limb venous thrombosis of the upper limbs active malignancy any other medical condition or congenital or traumatic injury involving either limb patients already on selenium medication patients participating in another clinical study related to lymphedema</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>